The purpose is to compare OAC naive patients commencing treatment with reduced dose NOAC compared to those initiating warfarin, to describe the risk of cardiovascular events including ischemic stroke/systemic embolism, intracranial hemorrhage, fatal bleeding, and other events such as kidney failure and acute kidney injury.
Changes to the permit: change of processors; extension of validity
Issuer of the original permit: Kela, Statistics Finland